



Kroger
Prescription
Plans

2021 Annual KPP Trend Report

2.0% *Overall
Trend*

Low Cost Generics & Clinical Innovation

By maximizing low-cost generics and implementing innovative clinical programs, our clients collectively achieved an industry leading overall trend.

1.2% *Traditional
Drug Spend*

Generic Dispensing Rate to 89.1%

- GDR Flat Year Over Year
- 4.1% Unit Price, -0.3% Utilization, -2.6% Drug Mix

4.0% *Specialty
Drug Spend*

Driving 51.2% of Total Plan Paid

- Specialty 360 Program decreased specialty drug spend by 20.4%
- -1.9% Unit Cost, 3.1% Utilization, 2.6% Drug Mix

800.917.4926
www.kpp-rx.com

Innovative Clinical Programs

Clinical Performance Based Guarantee – Suite of Clinical Programs that We Guarantee Will Lower Your Prescription Drug Spend

Specialty 360 – Dynamic Copay Program that Maximizes Copay Cards to Offset Costly Specialty and Non-Specialty Therapies

OTC Alternative Exclusion Program – Stop Covering Rx Drugs that are Available Over-The-Counter

High-Cost Generic Program – Switch Patients from High-Cost Generic Medication to Lower Cost Alternatives

Reference Based Pricing – Proactively Contains Cost in Select Drug Classes

Specialty Alternative Funding – Lower plan and patient cost for specialty medications by matching patients with alternative funding sources

Top 3 Drug Classes

Inflammatory Diseases, Diabetes and Neoplastic Disease

Forecast

Plaque Psoriasis – Variety of biologic agents on the market and expected in the pipeline, in addition to new advances in precision medicine technology

Diabetes – Increased competition with the introduction of biosimilar insulins into the market with interchangeability status

JAK Inhibitors – Several new approvals and expanded indications with increased utilization expected to grow in the coming year

Respiratory – Symbicort and Dulera may begin facing generic competition sometime in 2022